HAS after OLT can be treated endovascularly with high technical success and excellent primary assisted patency. This series represents the largest reported cohort of endovascular interventions for HAS to date. Initial use of a stent showed a strong trend toward decreasing the need for reintervention. Avoidance of hepatic artery thrombosis is possible in >95% of patients with endovascular treatment and close follow-up.

Thrombolysis followed by urgent CEA or CAS is not associated with an increased risk of complications in select patients who present with acute neurologic symptoms. Selection of patients is important; there was no ICH and only one death in each group for patients with minor to moderate ischemic stroke (NIHSS score <10).

No abstract

In primary and secondary CV prevention, the efficacy advantage of rosuvastatin was minimal, while its acquisition cost was higher, particularly in Colombia. The incremental cost-effectiveness ratios were, therefore, generally in favor of atorvastatin being the cost-effective option.

Changes of apoptosis-related molecules on ERK signaling pathway in KBD patients suggested that ERK signaling pathway might play important roles in molecular biology mechanism of KBD, and Na2SeO3 could promote activation of pRaf-1，pMek1/2 and pErk1/2. * This research is supported by National Natural Science Foundation (No. 30671820，81172610). Muscular-skeletal DisorDers-cost studies PMs14 BuDget iMPact of converting stanDarD treatMent of flail chest froM suPPortive theraPy to surgical fixation With contoureD titaniuM Plates in canaDian hosPitals